Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: June 2, 2010

Drug Name Review Type Class Manufacturer
Victoza New Drug Initial Review GLP-1 Receptor Agonist Novo Nordisk
Kalbitor New Drug Initial Review Orphan Biologic � for HAE Dyax
Intuniv New Drug Initial Review ADHD Agents Shire
Fanapt New Drug Initial Review Atypical Antipsychotic Novartis
Effient New Drug Initial Review Platelet Aggregation Inhibitor Eli Lilly
Ampyra New Drug Initial Review Multiple Sclerosis Agents Acorda
Xifaxan 550 New Drug Initial Review Antibiotic Salix
Cayston New Drug Initial Review Antibiotic Gilead
Renvela New Drug Appeal Phosphate Binder Genzyme
Byetta New Drug Appeal GLP-1 Receptor Agonist Amylin
Invega Sustenna New Drug Appeal Atypical Antipsychotic Ortho McNeil Janssen
Multaq New Drug Appeal Antiarrhythmic Sanofi
Twynsta New Drug Appeal Antihypertensive Combination Boehringer Ingelheim
Zemplar New Drug Appeal Hyperparathyroidism due to CKD Abbott
Toviaz New Drug Appeal Urinary Anti-Incontinence Pfizer
Vivitrol New Drug Appeal Opioid Antagonist Alkermes